6 results match your criteria: "University College London Cancer Institute and University College London Hospitals[Affiliation]"
Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.
Open Forum Infect Dis
August 2023
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Cytomegalovirus (CMV) is a common infection that can occur after allogeneic hematopoietic cell transplant (alloHCT), and this study examines how changes in CMV-specific immune responses in the first month post-transplant can predict infection risk and mortality.
- The study analyzed data from 226 alloHCT recipients, identifying key predictors of clinically significant CMV infection (CS-CMVi) such as decreased T-cell response to CMV antigens and factors like transplant type and use of corticosteroids.
- Findings suggest that a decline in CMV-specific immune responses, particularly from week 2 to week 4 after transplant, is linked to a higher risk of CMV infection and increased overall mortality among
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Clin Infect Dis
December 2020
Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically significant CMV infection (CS-CMVi).
Methods: The CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral therapy.
Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy.
Lancet Infect Dis
July 2019
Department of Haematology, University College London Cancer Institute and University College London Hospitals NHS Foundation Trust, London, UK.
Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown to be particularly challenging-with substantial inter-observer variability in the histopathological diagnosis of many tumour types. Here we present a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and demonstrate its application in a routine diagnostic setting.
View Article and Find Full Text PDFBackground: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.
Methods: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries.
Background: Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients.
Methods: TOPICAL was a double-blind, randomised, placebo-controlled, phase 3 trial, done at 78 centres in the UK.